The Role of Probiotics in Preventing Rebleeding in Patients with Esophagogastric Variceal Hemorrhage Secondary to Liver Cirrhosis
Objective To evaluate the preventive effect of probiotics on long-term rebleeding rates in patients with esophagogastric variceal hemorrhage secondary to liver cirrhosis after endoscopic treatment.Methods A total of 142 patients who presented with their first episode of esophagogastric variceal hemorrhage secondary to liver cirrhosis at Beijing Ditan Hospital between December 2018 and December 2019 were enrolled.Five patients with a history of primary liver cancer or other malignancies,seven patients who underwent transjugular intrahepatic portosystemic stent shunt(TIPSS)or splenectomy,three patients with peptic ulcers,three with severe data loss,and three who were lost to follow-up were excluded.Of the 142 included,129 received propranolol treatment before or after enrollment.Based on telephone interviews and prescription reviews,69 patients who had taken probiotics for ≥28 cDDD within one year were classified into the probiotic group,while 73 who had not were placed in the non-probiotic group.Results The overall one-year rebleeding rate was 10.56％(15/142).Significant differences were observed in RBC(2.96±0.79 vs.3.66±0.80,P=0.001),PLT(47.73±14.24 vs.94.79±88.47,P＜0.001),ALB(31.71±4.13 vs.35.54±4.97,P=0.007),and probiotic use(13.3％vs.52.8％,P＜0.001)between the rebleeding and non-rebleeding groups.The one-year rebleeding rate was significantly lower in the probiotic group compared to the non-probiotic group(2.9％vs.17.8％,P=0.004).Multivariate logistic regression analysis identified RBC and probiotic use as independent protective factors against rebleeding.Conclusion Probiotics may serve as a protective factor against rebleeding following endoscopic treatment of esophagogastric varices in patients with liver cirrhosis.
万方数据
维普
